Day: June 29, 2025

Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032, Growing at a CAGR of 9.9% from 2025, Says Meticulous Research®

Staff June 29, 2025

Market Growth Driven by Outsourcing Preferences, Advanced Manufacturing Technologies, Regulatory Compliance Expertise, and Industry 4.0 Integration REDDING, Calif., June 29,...

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

Staff June 29, 2025

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches...

Audien Atom Hearing Aid Releases 2025 Accessibility Update: Wireless Charging, Invisible Fit & Direct-to-Consumer Simplicity Reshape Hearing Aid Market

Staff June 29, 2025

The 2025 update to the Atom One and Atom 2 models introduces enhanced wireless charging, Comfort+ miniaturization, and multi-mode support...

Day: June 29, 2025

Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032, Growing at a CAGR of 9.9% from 2025, Says Meticulous Research®

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

Audien Atom Hearing Aid Releases 2025 Accessibility Update: Wireless Charging, Invisible Fit & Direct-to-Consumer Simplicity Reshape Hearing Aid Market

AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

You may have missed